Please use this identifier to cite or link to this item: https://doi.org/10.1517/13543784.2012.703178
Title: Clinical utility of neuroprotective agents in neurodegenerative diseases: Current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis
Authors: Dunkel, P.
Chai, C.L. 
Sperlágh, B.
Huleatt, P.B.
Mátyus, P.
Keywords: Alzheimer's disease
Amyotrophic lateral sclerosis
Huntington's disease
Multi-target-directed ligands
Neurodegenerative
Neuroprotective
Parkinson's disease
Issue Date: Sep-2012
Citation: Dunkel, P., Chai, C.L., Sperlágh, B., Huleatt, P.B., Mátyus, P. (2012-09). Clinical utility of neuroprotective agents in neurodegenerative diseases: Current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs 21 (9) : 1267-1308. ScholarBank@NUS Repository. https://doi.org/10.1517/13543784.2012.703178
Abstract: Introduction: According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), "neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients" [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive. Areas covered: The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases. Expert opinion: Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology. © 2012 Informa UK, Ltd.
Source Title: Expert Opinion on Investigational Drugs
URI: http://scholarbank.nus.edu.sg/handle/10635/106630
ISSN: 13543784
DOI: 10.1517/13543784.2012.703178
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

46
checked on Jun 18, 2018

WEB OF SCIENCETM
Citations

43
checked on Jun 5, 2018

Page view(s)

46
checked on May 25, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.